Publication:
[Oseltamivir for the treatment of influenza in children and adolescents].

dc.contributor.authorTagarro, Alfredo
dc.contributor.authorCruz-Cañete, Marta
dc.contributor.authorOtheo, Enrique
dc.contributor.authorLaunes, Cristian
dc.contributor.authorCouceiro, José Antonio
dc.contributor.authorPérez, Carlos
dc.contributor.authorAlfayate, Santiago
dc.contributor.authoren nombre del Grupo de trabajo de Infecciones Respiratorias de la Sociedad Española de Infectología Pediátrica (SEIP)
dc.contributor.authorMiembros del Grupo de Trabajo de Infecciones Respiratorias de la SEIP que han participado en la revisión del manuscrito
dc.date.accessioned2023-01-25T13:31:45Z
dc.date.available2023-01-25T13:31:45Z
dc.date.issued2019-02-21
dc.description.abstractInfluenza is a generally a benign disease, but occasionally it can cause serious complications. There is controversy about the benefits of antiviral treatment. To provide some recommendations on the treatment with oseltamivir in paediatric patients with influenza, based on the best data available and valid in our environment. The Respiratory Infections Group of the Spanish Society of Paediatric Infectious Diseases carried out a review of the literature. The findings were analysed using the GRADE methodology, and recommendations were made. The systematic use of diagnostic tests for influenza in the outpatient setting, or in the emergency room, in immunocompetent patients with a compatible clinical picture is not recommended. If the aim is to prevent serious events, the use of antivirals is not recommended for the vast majority of healthy and asthmatic patients with influenza or suspected seasonal flu. The systematic use of oseltamivir in patients admitted to hospital with influenza is not recommended. Oseltamivir treatment is recommended in any patients with influenza and pneumonia or severe illness, and critically ill patients, especially during the first 48hours of illness. The treatment of patients with risk factors is recommended, considering their underlying disease. Influenza vaccination, together with basic isolation measures, continue to be the main tool in the prevention of influenza. In some situations, there are sufficient data to issue clear recommendations. In other situations, the data are incomplete, and only allows weak recommendations.
dc.identifier.doi10.1016/j.anpedi.2019.01.009
dc.identifier.essn2341-2879
dc.identifier.pmid30797703
dc.identifier.unpaywallURLhttps://doi.org/10.1016/j.anpedi.2019.01.009
dc.identifier.urihttp://hdl.handle.net/10668/13617
dc.issue.number5
dc.journal.titleAnales de pediatria
dc.journal.titleabbreviationAn Pediatr (Engl Ed)
dc.language.isoes
dc.organizationAPES Alto Guadalquivir
dc.page.number317.e1-317.e8
dc.pubmedtypeJournal Article
dc.pubmedtypeReview
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/
dc.subjectAntivirales
dc.subjectAntivirals
dc.subjectGripe
dc.subjectInfluenza
dc.subjectOseltamivir
dc.subjectZanamivir
dc.subject.meshAdolescent
dc.subject.meshAge Factors
dc.subject.meshAntiviral Agents
dc.subject.meshChild
dc.subject.meshCritical Illness
dc.subject.meshHumans
dc.subject.meshInfluenza, Human
dc.subject.meshOseltamivir
dc.subject.meshRisk Factors
dc.subject.meshTime Factors
dc.title[Oseltamivir for the treatment of influenza in children and adolescents].
dc.title.alternativeOseltamivir para el tratamiento de la gripe en niños y adolescentes.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number90
dspace.entity.typePublication

Files